Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureIbrahim Taha Aldoss, Tsewang Tashi, Wilson I. Gonsalves, Ranin K. Kalaiah, Peter T. Silberstein, Shanmuga P. Subbiah
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database
10.1016/s1072-7515(99)00075-7 · 1999
The National Cancer Database report on pancreatic, cancer
10.1002/1097-0142(19951101)76:9<1671::aid-cncr2820760926>3.0.co;2-r · 1995
Cancer statistics, 2009
10.3322/caac.20006 · 2009
Metastatic pancreatic cancer 2008: is the glass less empty?
10.1634/theoncologist.2007-0181 · 2008
Advanced pancreatic cancinoma: current treatment and future challenges
10.1038/nrclinonc.2009.236 · 2010
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
10.1200/jco.1997.15.6.2403 · 1997
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
10.1200/jco.2006.07.9525 · 2007
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale
10.1002/cncr.10323.abs · 2002
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
10.1200/jco.2004.12.082 · 2004
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial
10.1200/jco.2005.06.023 · 2005
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
10.1093/annonc/mdi309 · 2005
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
10.1200/jco.2006.07.0201 · 2006
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
10.1200/jco.2005.05.1490 · 2006
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
10.1038/sj.bjc.6603301 · 2006
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
10.1200/jco.2009.24.2446 · 2009
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study
10.1200/jco.2009.25.4433 · 2010
Underrepresentation of patients 65years of age or older in cancer-treatment trials
10.1056/nejm199912303412706 · 1999
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
10.1093/annonc/mdh344 · 2004
Prognosis and management strategies of lymphatic neoplasias in the elderly. I. Aggressive non-Hodgkin's lymphomas
10.1159/000011855 · 1998
Influence of age on the treatment of limited-stage small-cell lung cancer
10.1200/jco.1996.14.3.821 · 1996
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial
10.1093/jnci/94.3.173 · 2002
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
10.1016/0895-4356(92)90133-8 · 1992
Risk adjustment in outcome assessment: the Charlson comorbidity index
10.1055/s-0038-1634956 · 1993
Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability
10.1097/00005650-199611000-00004 · 1996
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
10.1016/0021-9681(87)90171-8 · 1987
Therapeutic options for elderly patients with advanced non-small cell lung cancer
10.1016/j.ctrv.2008.10.008 · 2009
Comorbidity and functional status are independent in older cancer patients
10.1200/jco.1998.16.4.1582 · 1998
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer
10.1200/jco.2000.18.13.2529 · 2000
Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study
10.1093/annonc/mdi368 · 2005
Survival associated with5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer
10.7326/0003-4819-136-5-200203050-00007 · 2002
Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: metaanalysis of three trials investigating 5-FU and irinotecan
2006
Gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a multicenter phase II study
10.1016/s0169-5002(99)00098-7 · 2000
Safety profile of gemcitabine
10.1097/00001813-199512006-00005 · 1995
Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age
1997
Unresolved referenced work
Kept as external metadata until matched
No additional external references are available.